Morgan Stanley’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-8,091
| Closed | -$5K | – | 6946 |
|
|
2018
Q4 | $5K | Sell |
8,091
-1,593
| -16% | -$1.65K | ﹤0.01% | 6323 |
|
|
2018
Q3 | $12K | Sell |
9,684
-106,172
| -92% | -$165K | ﹤0.01% | 6280 |
|
|
2018
Q2 | $156K | Buy |
115,856
+38,489
| +50% | +$59K | ﹤0.01% | 5621 |
|
|
2018
Q1 | $112K | Buy |
77,367
+417
| +0.5% | +$871 | ﹤0.01% | 5674 |
|
|
2017
Q4 | $173K | Buy |
76,950
+29,768
| +63% | +$75.3K | ﹤0.01% | 5463 |
|
|
2017
Q3 | $160K | Buy |
47,182
+7,963
| +20% | +$26.8K | ﹤0.01% | 5442 |
|
|
2017
Q2 | $139K | Sell |
39,219
-2,343
| -6% | -$7.72K | ﹤0.01% | 5502 |
|
|
2017
Q1 | $141K | Sell |
41,562
-33,503
| -45% | -$130K | ﹤0.01% | 5477 |
|
|
2016
Q4 | $345K | Buy |
75,065
+62,551
| +500% | +$258K | ﹤0.01% | 5119 |
|
|
2016
Q3 | $53K | Buy |
12,514
+5,230
| +72% | +$16.9K | ﹤0.01% | 5567 |
|
|
2016
Q2 | $17K | Sell |
7,284
-175
| -2% | -$633 | ﹤0.01% | 5918 |
|
|
2016
Q1 | $34K | Sell |
7,459
-145
| -2% | -$561 | ﹤0.01% | 5758 |
|
|
2015
Q4 | $30K | Sell |
7,604
-88
| -1% | -$405 | ﹤0.01% | 5910 |
|
|
2015
Q3 | $29K | Buy |
7,692
+740
| +11% | +$3.4K | ﹤0.01% | 5931 |
|
|
2015
Q2 | $31K | Buy |
6,952
+3,004
| +76% | +$28.8K | ﹤0.01% | 6019 |
|
|
2015
Q1 | $27K | Buy |
3,948
+2,988
| +311% | +$14.8K | ﹤0.01% | 5986 |
|
|
2014
Q4 | $3K | Buy |
+960
| New | +$3.87K | ﹤0.01% | 6424 |
|
Morgan Stanley's AST Position: Q1 2019 in Review
Morgan Stanley sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 8,091 shares — an estimated $5K sold.
Morgan Stanley first reported a position in AST in Q4 2014 and held it in 17 quarters. The position peaked at $345K in Q4 2016. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Morgan Stanley reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Morgan Stanley sold 8,091 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $5K.
- Morgan Stanley first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 17 quarters.
- Morgan Stanley's Asterias Biotherapeutics Inc. Series A position peaked at $345K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Morgan Stanley's 13F filing for Q1 2019, filed 15 May 2019.